C Arnaud1, P Gauthier, C Gottesmann. 1. Laboratoire de Psychophysiologie, Faculté des Sciences, Université de Nice-Sophia Antipolis, 06108 Nice, France.
Abstract
RATIONALE: gamma-Aminobutyric acid (GABA) is the main inhibitory transmitter of the brain. The involvement of GABAA and GABAB receptors in sleep-waking processes is well established. OBJECTIVES: This research studied the influence of GABAC receptors. METHODS: The rats were randomly infused in the fourth ventricle with vehicle and 25, 50, and 100 micrograms (1,2,5,6,-tetrahydropyridine)-methylphosphinic acid (TPMPA), a specific antagonist of GABAC receptors. RESULTS: Principally at 50 micrograms, the molecule induced an increase of waking from 44.7% to 61.7% (P < 0.003), which was the consequence of enhancement of both active and quiet wakefulness. Total slow wave sleep was decreased, particularly the slow-wave stage from 39% to 27.7% (P < 0.02). Paradoxical sleep was also decreased from 14.5% to 9.1% (P < 0.01). CONCLUSIONS: GABAC receptors are also involved in sleep-waking regulation. Since the sensitivity of GABAC receptors to GABA is much higher than that of GABAA and GABAB receptors, GABAC receptor modulators could be potential medications acting at low doses with fewer side effects.
RATIONALE: gamma-Aminobutyric acid (GABA) is the main inhibitory transmitter of the brain. The involvement of GABAA and GABAB receptors in sleep-waking processes is well established. OBJECTIVES: This research studied the influence of GABAC receptors. METHODS: The rats were randomly infused in the fourth ventricle with vehicle and 25, 50, and 100 micrograms (1,2,5,6,-tetrahydropyridine)-methylphosphinic acid (TPMPA), a specific antagonist of GABAC receptors. RESULTS: Principally at 50 micrograms, the molecule induced an increase of waking from 44.7% to 61.7% (P < 0.003), which was the consequence of enhancement of both active and quiet wakefulness. Total slow wave sleep was decreased, particularly the slow-wave stage from 39% to 27.7% (P < 0.02). Paradoxical sleep was also decreased from 14.5% to 9.1% (P < 0.01). CONCLUSIONS: GABAC receptors are also involved in sleep-waking regulation. Since the sensitivity of GABAC receptors to GABA is much higher than that of GABAA and GABAB receptors, GABAC receptor modulators could be potential medications acting at low doses with fewer side effects.
Authors: Navnath Gavande; Izumi Yamamoto; Noeris K Salam; Tu-Hoa Ai; Peter M Burden; Graham A R Johnston; Jane R Hanrahan; Mary Chebib Journal: ACS Med Chem Lett Date: 2010-10-19 Impact factor: 4.345
Authors: Izumi Yamamoto; Nathan Absalom; Jane E Carland; Munikumar R Doddareddy; Navnath Gavande; Graham A R Johnston; Jane R Hanrahan; Mary Chebib Journal: ACS Chem Neurosci Date: 2012-04-26 Impact factor: 4.418
Authors: J E Carland; I Yamamoto; J R Hanrahan; H Abdel-Halim; T M Lewis; N Absalom; M Chebib Journal: J Mol Neurosci Date: 2014-05-10 Impact factor: 3.444
Authors: Mary Chebib; Tina Hinton; Katrina L Schmid; Darren Brinkworth; Haohua Qian; Susana Matos; Hye-Lim Kim; Heba Abdel-Halim; Rohan J Kumar; Graham A R Johnston; Jane R Hanrahan Journal: J Pharmacol Exp Ther Date: 2008-11-04 Impact factor: 4.030
Authors: Mary Chebib; Navnath Gavande; Kit Yee Wong; Anna Park; Isabella Premoli; Kenneth N Mewett; Robin D Allan; Rujee K Duke; Graham A R Johnston; Jane R Hanrahan Journal: Neurochem Res Date: 2009-04-23 Impact factor: 3.996
Authors: Izumi Yamamoto; Jane E Carland; Katherine Locock; Navnath Gavande; Nathan Absalom; Jane R Hanrahan; Robin D Allan; Graham A R Johnston; Mary Chebib Journal: ACS Chem Neurosci Date: 2012-01-13 Impact factor: 4.418